Overview
Hawkinsinuria is an extremely rare inherited disorder of tyrosine metabolism caused by a defect in the enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD), encoded by the HPD gene. Unlike most other inborn errors of tyrosine catabolism, hawkinsinuria follows an autosomal dominant inheritance pattern. The condition is named after the Hawkins family, in whom it was first described. The enzymatic defect leads to the accumulation of an unusual amino acid metabolite called hawkinsin (2-L-cysteinyl-S-yl-1,4-dihydroxycyclohex-5-en-1-yl acetic acid) in the urine, along with other abnormal metabolites including 4-hydroxycyclohexylacetic acid. The disorder primarily affects the metabolic system, specifically the tyrosine degradation pathway in the liver. In infancy, affected individuals may present with failure to thrive, metabolic acidosis, and elevated blood tyrosine levels, particularly when exposed to a high-protein diet or standard infant formula. Symptoms in infancy can include poor weight gain, lethargy, and a characteristic body odor resembling a swimming pool (due to abnormal metabolites). Interestingly, many affected adults are clinically asymptomatic, with the biochemical abnormality (hawkinsinuria) persisting but without significant clinical consequences. Treatment during infancy primarily involves dietary management, specifically the restriction of phenylalanine and tyrosine intake. Breastfeeding has been noted to be protective, as breast milk has a relatively low protein content compared to standard infant formulas. With appropriate dietary management during the vulnerable infantile period, affected children typically improve and may become clinically well, though they continue to excrete hawkinsin in their urine. Supplementation with vitamin C (ascorbic acid) has also been reported to be beneficial, as it may help support residual enzyme activity. Long-term prognosis appears to be favorable, with most individuals leading normal lives after the critical infantile period.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Hawkinsinuria.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hawkinsinuria at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hawkinsinuria.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hawkinsinuria.
Community
No community posts yet. Be the first to share your experience with Hawkinsinuria.
Start the conversation →Latest news about Hawkinsinuria
No recent news articles for Hawkinsinuria.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hawkinsinuria
What is Hawkinsinuria?
Hawkinsinuria is an extremely rare inherited disorder of tyrosine metabolism caused by a defect in the enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD), encoded by the HPD gene. Unlike most other inborn errors of tyrosine catabolism, hawkinsinuria follows an autosomal dominant inheritance pattern. The condition is named after the Hawkins family, in whom it was first described. The enzymatic defect leads to the accumulation of an unusual amino acid metabolite called hawkinsin (2-L-cysteinyl-S-yl-1,4-dihydroxycyclohex-5-en-1-yl acetic acid) in the urine, along with other abnormal metabolites
How is Hawkinsinuria inherited?
Hawkinsinuria follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hawkinsinuria typically begin?
Typical onset of Hawkinsinuria is infantile. Age of onset can vary across affected individuals.